Pulmonary arterial hypertension
- PMID: 16581695
- DOI: 10.1080/07853890600622143
Pulmonary arterial hypertension
Abstract
Pulmonary arterial hypertension is a disease of the small pulmonary arteries characterized by vascular narrowing and increased pulmonary vascular resistance, which eventually leads to right ventricular failure. Vasoconstriction, vascular proliferation, remodeling of the pulmonary vessels, and thrombosis are all contributing factors to the increased vascular resistance seen in this disease. Pulmonary arterial hypertension develops as a sporadic disease (idiopathic), as an inherited disorder (familial), or in association with certain conditions (collagen vascular diseases, portal hypertension, human immunodeficiency virus infection, congenital systemic-to-pulmonary shunts, ingestion of drugs or dietary products, or persistent fetal circulation). The pathogenesis of pulmonary arterial hypertension is a complicated, multifactorial process. It seems doubtful that any one factor alone is sufficient to activate the necessary pathways leading to the development of this disease. Rather, clinically apparent pulmonary arterial hypertension most likely develops after a second insult occurs in an individual who is already susceptible owing to genetic factors, environmental exposures, or acquired disorders. Currently, there is no cure for pulmonary arterial hypertension but several novel therapeutic options are now available that can improve symptoms and increase survival.
Similar articles
-
Diagnosis and management of pulmonary arterial hypertension: Implications for respiratory care.Respir Care. 2006 Apr;51(4):368-81. Respir Care. 2006. PMID: 16563191
-
YC-1 attenuates hypoxia-induced pulmonary arterial hypertension in mice.Pulm Pharmacol Ther. 2011 Dec;24(6):638-46. doi: 10.1016/j.pupt.2011.09.003. Epub 2011 Sep 24. Pulm Pharmacol Ther. 2011. PMID: 21963997
-
Lysyl oxidases play a causal role in vascular remodeling in clinical and experimental pulmonary arterial hypertension.Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1446-58. doi: 10.1161/ATVBAHA.114.303534. Epub 2014 May 15. Arterioscler Thromb Vasc Biol. 2014. PMID: 24833797
-
[Pulmonary arterial hypertension. Part I: pathobiologic, pathophysiologic, clinical and diagnostic aspects].G Ital Cardiol (Rome). 2009 May;10(5):271-300. G Ital Cardiol (Rome). 2009. PMID: 19537440 Review. Italian.
-
Pulmonary arterial hypertension (PAH) in connective tissue diseases.Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii11-3. doi: 10.1093/rheumatology/kel291. Rheumatology (Oxford). 2006. PMID: 16987822 Review.
Cited by
-
Transgenic expression of human matrix metalloproteinase-1 attenuates pulmonary arterial hypertension in mice.Clin Sci (Lond). 2012 Jan;122(2):83-92. doi: 10.1042/CS20110295. Clin Sci (Lond). 2012. Retraction in: Clin Sci (Lond). 2017 Jan 1;131(1):25. doi: 10.1042/CS20160295RET. PMID: 21793800 Free PMC article. Retracted.
-
VIP gene deletion in mice causes cardiomyopathy associated with upregulation of heart failure genes.PLoS One. 2013 May 20;8(5):e61449. doi: 10.1371/journal.pone.0061449. Print 2013. PLoS One. 2013. PMID: 23700405 Free PMC article.
-
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.Physiol Genomics. 2008 Apr 22;33(2):278-91. doi: 10.1152/physiolgenomics.00169.2007. Epub 2008 Feb 26. Physiol Genomics. 2008. PMID: 18303084 Free PMC article.
-
Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells.Vasc Health Risk Manag. 2010 Sep 7;6:723-34. doi: 10.2147/vhrm.s11129. Vasc Health Risk Manag. 2010. PMID: 20859543 Free PMC article.
-
Effect of chronic sodium nitrite therapy on monocrotaline-induced pulmonary hypertension.Nitric Oxide. 2012 Jun 30;27(1):1-8. doi: 10.1016/j.niox.2012.02.004. Epub 2012 Mar 14. Nitric Oxide. 2012. PMID: 22426035 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical